Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH

Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today announced that they have entered into an exclusive worldwide licensing ...
Science Daily

NMR-guided optimization of lipid nanoparticles for enhanced siRNA delivery

siRNA therapies show promise for treating diseases like cancer and genetic disorders, but their effectiveness depends on proper delivery. A recent study found that the method of mixing siRNA with ...
The Pharma Letter

Madrigal expands its MASH pipeline via Ribo deal

US biopharma Madrigal Pharmaceuticals, which is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), has announced an exclusive global license ...
Nasdaq

Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology ...

Avidity expands its leading RNA delivery technology into precision cardiology with two new wholly-owned development candidates targeting rare genetic cardiomyopathies: AOC 1086 to treat PLN ...

Suzhou Ribo Life Science Co., Ltd.: Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH

SUZHOU, China and MÖLNDAL, Sweden, Feb. 11, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today announced ...
Pharmabiz

Ribo and Ribocure enter exclusive global licensing agreement with Madrigal for novel siRNA therapeutics targeting MASH

Ribo and Ribocure enter exclusive global licensing agreement with Madrigal for novel siRNA therapeutics targeting MASH: Suzhou, China Thursday, February 12, 2026, 15:00 Hrs [IST] ...